These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16397559)

  • 21. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance.
    Roden M
    Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):335-48. PubMed ID: 16932311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of n-3 polyunsaturated fatty acids on metabolic control and vascular reactivity in the type 2 diabetic ob/ob mouse.
    Mustad VA; Demichele S; Huang YS; Mika A; Lubbers N; Berthiaume N; Polakowski J; Zinker B
    Metabolism; 2006 Oct; 55(10):1365-74. PubMed ID: 16979408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isosteviol increases insulin sensitivity and changes gene expression of key insulin regulatory genes and transcription factors in islets of the diabetic KKAy mouse.
    Nordentoft I; Jeppesen PB; Hong J; Abudula R; Hermansen K
    Diabetes Obes Metab; 2008 Sep; 10(10):939-49. PubMed ID: 18201205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of obesity-associated insulin resistance: many choices on the menu.
    Qatanani M; Lazar MA
    Genes Dev; 2007 Jun; 21(12):1443-55. PubMed ID: 17575046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain insulin signalling in the regulation of energy balance and peripheral metabolism.
    Diamant M
    Ideggyogy Sz; 2007 Mar; 60(3-4):97-108. PubMed ID: 17451048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of association of CPT1A polymorphisms or haplotypes on hepatic lipid content or insulin resistance in Japanese individuals with type 2 diabetes mellitus.
    Hirota Y; Ohara T; Zenibayashi M; Kuno S; Fukuyama K; Teranishi T; Kouyama K; Miyake K; Maeda E; Kasuga M
    Metabolism; 2007 May; 56(5):656-61. PubMed ID: 17445541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of ChREBP in hepatic steatosis and insulin resistance.
    Denechaud PD; Dentin R; Girard J; Postic C
    FEBS Lett; 2008 Jan; 582(1):68-73. PubMed ID: 17716660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Insulin signaling and insulin resistance].
    Ferré P
    Therapie; 2007; 62(4):277-84. PubMed ID: 17983553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.
    Hong EG; Jung DY; Ko HJ; Zhang Z; Ma Z; Jun JY; Kim JH; Sumner AD; Vary TC; Gardner TW; Bronson SK; Kim JK
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1687-96. PubMed ID: 17911348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptional regulation of the plasminogen activator inhibitor type 1--with an emphasis on negative regulation.
    Nagamine Y
    Thromb Haemost; 2008 Dec; 100(6):1007-13. PubMed ID: 19132223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postprandial fatty acid metabolism in the development of lipotoxicity and type 2 diabetes.
    Carpentier AC
    Diabetes Metab; 2008 Apr; 34(2):97-107. PubMed ID: 18353699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ontogenetic characteristics of enzyme activities and plasma metabolites in C57BL/6J:Jcl mice deficient in insulin receptor substrate 2.
    Hashimoto H; Arai T; Takeguchi A; Hioki K; Ohnishi Y; Kawai K; Ito M; Suzuki R; Yamauchi T; Ohsugi M; Saito M; Ueyama Y; Tobe K; Kadowaki T; Tamaoki N; Kosaka K
    Comp Med; 2006 Jun; 56(3):176-87. PubMed ID: 16774126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular basis of insulin action.
    González-Sánchez JL; Serrano-Ríos M
    Drug News Perspect; 2007 Oct; 20(8):527-31. PubMed ID: 18080040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.
    Holland WL; Brozinick JT; Wang LP; Hawkins ED; Sargent KM; Liu Y; Narra K; Hoehn KL; Knotts TA; Siesky A; Nelson DH; Karathanasis SK; Fontenot GK; Birnbaum MJ; Summers SA
    Cell Metab; 2007 Mar; 5(3):167-79. PubMed ID: 17339025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling.
    Cho CY; Koo SH; Wang Y; Callaway S; Hedrick S; Mak PA; Orth AP; Peters EC; Saez E; Montminy M; Schultz PG; Chanda SK
    Cell Metab; 2006 May; 3(5):367-78. PubMed ID: 16679294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Welcoming Foxa2 in the bile acid entourage.
    Moschetta A
    Cell Metab; 2008 Oct; 8(4):276-8. PubMed ID: 18840356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents.
    Turner N; Bruce CR; Beale SM; Hoehn KL; So T; Rolph MS; Cooney GJ
    Diabetes; 2007 Aug; 56(8):2085-92. PubMed ID: 17519422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic fat is not associated with beta-cell function or postprandial free fatty acid response.
    Rijkelijkhuizen JM; Doesburg T; Girman CJ; Mari A; Rhodes T; Gastaldelli A; Nijpels G; Dekker JM
    Metabolism; 2009 Feb; 58(2):196-203. PubMed ID: 19154952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythrocyte insulin receptor abnormalities.
    Susheela L; Ramachandran A; Mohan V; Sheeja ; Viswanathan M
    J Assoc Physicians India; 1987 May; 35(5):337-9. PubMed ID: 3320021
    [No Abstract]   [Full Text] [Related]  

  • 40. Possible post-receptor defects in NIDDM: second messengers.
    Saltiel AR
    Prog Clin Biol Res; 1988; 265():43-51. PubMed ID: 3043446
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.